TapImmune Inc. (NASDAQ:MRKR) shares shot up 6.4% on Thursday . The stock traded as high as $7.73 and last traded at $7.69. 477,220 shares changed hands during mid-day trading, an increase of 29% from the average session volume of 369,924 shares. The stock had previously closed at $7.23.
Several brokerages have recently weighed in on MRKR. Roth Capital began coverage on shares of TapImmune in a research report on Thursday, May 30th. They issued a “buy” rating and a $10.00 price objective on the stock. WBB Securities raised shares of TapImmune from a “buy” rating to a “strong-buy” rating and set a $7.29 price objective on the stock in a research report on Friday, March 29th. Janney Montgomery Scott began coverage on shares of TapImmune in a research report on Friday, March 1st. They issued a “buy” rating and a $6.22 price objective on the stock. Zacks Investment Research raised shares of TapImmune from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research report on Thursday, May 30th. Finally, ValuEngine lowered shares of TapImmune from a “buy” rating to a “hold” rating in a research report on Friday, June 7th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $9.25.
The company has a debt-to-equity ratio of 0.01, a current ratio of 19.73 and a quick ratio of 19.73. The firm’s 50 day moving average price is $6.14. The firm has a market cap of $360.20 million, a price-to-earnings ratio of -4.74 and a beta of 0.04.
A hedge fund recently raised its stake in TapImmune stock. Riggs Asset Managment Co. Inc. grew its position in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 45,919 shares of the company’s stock after purchasing an additional 18,650 shares during the quarter. Riggs Asset Managment Co. Inc. owned about 0.10% of TapImmune worth $303,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 33.64% of the company’s stock.
About TapImmune (NASDAQ:MRKR)
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Read More: Why is Cost of Capital Important?
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.